Biogen Wins OK for Psoriasis Drug
From Times Wire Services
Biogen Inc. won U.S. approval to sell a treatment for psoriasis that lacks side effects of older drugs and could bring it $500 million in annual sales.
Amevive, an injected medicine, won Food and Drug Administration clearance for patients with a form of the skin disease called moderate-to-severe chronic plaque psoriasis.
The drug is expected to face competition from Amgen Inc.’s arthritis drug Enbrel, which is being studied as a psoriasis treatment.
